U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287917) titled 'Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors' on Nov. 24.
Brief Summary: This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups:
* Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and capivasertib
* Cohort 2: Patients with unresectable or metastatic cutaneous melanoma receiving pembrolizumab
The Phase 1b portion will find the recommended Phase 2 dose (RP2D). The Phase 2 portion will further evaluate clinical activity at...